ADMA Q2 2017 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+49.6% YoY

Gross Profit

-$934,618-27.5% margin

Operating Income

-$8M-247.2% margin

Net Income

-$9M-265.8% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+29.3%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$311,363

Balance Sheet

Total Assets

$85M

Total Liabilities

$57M

Stockholders' Equity

$28M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+49.6%
Gross Profit	-$934,618	$927,503	-200.8%
Operating Income	-$8M	-$5M	-53.0%
Net Income	-$9M	-$6M	-50.3%

Revenue Segments

Plasma Collection Center Member

$3M83%

ADMA BioManufacturing

$539,22316%

Corporate Member

$35,7081%